ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
Pre-market 07:56:56 | |||
| 891.5 USD | +0.73% |
|
892.3 | +0.09% |
| 12:30pm | Lilly files additional lawsuits over US sales of counterfeit Mounjaro | RE |
| 12:00pm | Food companies with Ozempic-friendly snacks and meals wade carefully into weight-loss waters | RE |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5
USD
Average target price
855.4
USD
Spread / Average Target
-4.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.93% | 803B | |
| +41.27% | 631B | |
| -7.08% | 351B | |
| +17.40% | 324B | |
| +10.58% | 303B | |
| +16.68% | 243B | |
| +2.21% | 228B | |
| +10.31% | 217B | |
| +6.24% | 164B | |
| -4.79% | 155B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly Gets FDA Approval for Selpercatinib to Treat Thyroid Cancer
